P3. Viral studies (natural history and therapeutic)
Oral Abstract Submission
Joseph B. Domachowske, MD
Dr.
SUNY Upstate Medical University
Syracuse, NY
Disclosure: AstraZeneca: Scientific Research Study Investigator
Veronique Bianco, MS
Statistician
GSK
Rockville, MD
Disclosure: GlaxoSmithKline: Employee, Shareholder
Ana Ceballos, MD
Dr.
Instituto Medico Rio Cuarto
Rio Cuarto, Cordoba, Argentina
Disclosure: GSK: Grant/Research Support
Luis Cousin, MD
MD/Principal Investigator
Tecnologia en Investigación
San Pedro Sula, Cortes, Honduras
Disclosure: Nothing to disclose
Ulises D'Andrea, MD
Sub-investigator
Instituto Medico Rio Cuarto
Rio Cuarto, Cordoba, Argentina
Disclosure: Nothing to disclose
Ilse Dieussaert, IR
Head of Maternal Immunization, GSK Vaccines USA
GSK
Rockville, MD
Disclosure: GSK: Employee
Janet A. Englund, MD
Professor
Seattle Children's Hospital/Univ. of Washington
Seattle, Washington
Disclosure: AstraZeneca: Grant/Research Support
Chimerix: Grant/Research Support
GlaxoSmithKline: Consultant, Grant/Research Support
Meissa Vaccines: Consultant
Merck: Grant/Research Support
Novavax: Grant/Research Support
Sanofi Pasteur: Consultant
Sanjay Gandhi, MD
Vice President
GSK
Mumbai, Maharashtra, India
Disclosure: GSK: Employee, Shareholder
Gerco Haars, PhD
Senior Manager Epidemiology
GSK
Wavre, Brabant Wallon, Belgium
Disclosure: GSK: Other Financial or Material Support, employee at time of study start
Lisa Jose, MBchb
Dr.
Faculty of Health Sciences, University of the Witwatersrand
Johannesburg, Gauteng, South Africa
Disclosure: Nothing to disclose
Nicola Klein, MD, PhD
Director, Kaiser Permanente Vaccine Study Center and Senior Research Scientist
Kaiser Permanente Northern California
Oakland, CA
Disclosure: GlaxoSmithKline: Grant/Research Support
Merck & Co: Grant/Research Support
Pfizer: Grant/Research Support
Protein Science (now Sanofi Pasteur): Grant/Research Support
Sanofi Pasteur: Grant/Research Support
Joanne M. Langley, MD
Professor of Pediatrics and Community Health and Epidemiology
Dalhousie University
Halifax, NS, Canada
Disclosure: GSK: Research Grant or Support
GSK: Research Grant or Support
Medicago: Research Grant or Support
PREVENT: Research Grant or Support
Sanofi: Advisor or Review Panel member
Shabir A. Madhi, MBBCh, FCPaeds (SA), PhD
Professor of Vaccinology
Faculty of Health Sciences, University of the Witwatersrand
Johannesburg, Gauteng, South Africa
Disclosure: GSK: Grant/Research Support
Koen Maleux, Bio-Engineer
Project Manager
GSK
Wavre, Brabant Wallon, Belgium
Disclosure: GSK: Employee
Thi Lien-Anh Nguyen, PhD
Senior Scientist
GSK
Wavre, Brabant Wallon, Belgium
Disclosure: GSK: Employee, Shareholder
Thanyawee Puthanakit, MD
Associate Professor
Faculty of Medicine, Chulalongkorn University
Bangkok, Krung Thep, Thailand
Disclosure: GSK: Grant/Research Support, Speaker's Bureau
Peter Silas, MD
Principal Investigator
Wee Care Pediatrics
Syracuse, UT
Disclosure: GSK: Independent Contractor
Auchara Tangsathapornpong, MD
Associate Professor
Faculty of Medicine, Thammasat University
Pathum Thani, Pathum Thani, Thailand
Disclosure: Nothing to disclose
Jamaree Teeratakulpisarn, MD
Professor
Khon Kaen University
Khon Kaen, Khon Kaen, Thailand
Disclosure: Nothing to disclose
Miia Virta, MD, PhD
Dr.
Vaccine Research Center, Tampere University
Tampere, Pirkanmaa, Finland
Disclosure: Nothing to disclose
Khalequ Zaman, MD
Dr.
International Center for Diarrhoeal Disease Research
Dhaka, Dhaka, Bangladesh
Disclosure: Nothing to disclose
Background :
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections (LRTI) during infancy worldwide. High cord blood (CB) concentrations of anti-RSV neutralizing antibody (nAb) may attenuate, delay, or prevent infant infection. We report RSV A and B nAb concentrations in CB and serum from a birth cohort at different time points through 2 years of age.
Methods :
Between 2013 and 2017, newborns from 8 countries were studied prospectively from birth to 2 years of age (NCT01995175). CB was collected at birth for the entire cohort. A subcohort of children were randomly assigned to have one blood sample collected again at either 2, 4, 6, 12, 18, or 24 months of age. Sera were analyzed for RSV A and B nAb concentrations by serum neutralization assay. Active surveillance was used to identify LRTIs during the 2-year follow-up as previously reported.
Results :
2401 newborns were enrolled and followed up. > 99% of infants had detectable CB RSV A and B nAb. Geometric mean antibody titers (GMTs) varied by country, but were overall higher for RSV B than for RSV A (327 vs 251; Figure 1). The lowest GMTs were seen from CB sera collected from South African newborns (197 RSV A, 255 RSV B); Canadian newborns had the highest RSV A GMT (383), while Hondurans had the highest RSV B GMT (460). 1380 infants provided follow-up serum nAb results as part of the subcohort. (Figure 2). Dramatic waning of GMTs was evident, with a ~3-fold drop in GMTs at 2 months of age, and an additional ~2-fold drop between 2 and 4 months of age. At 6 and 12 months of age, 71% and 50% of infants had RSV A nAb and GMTs were at a nadir of 14. At 6, 12, and 18 months of age, RSV B nAb was detected in 98%, 69%, and 63% of infants, respectively. The RSV B nAb nadir GMT of 20 was observed at 12 months of age, while the 6- and 18-month RSV B nAb GMTs were 30 and 31, respectively. 1017 LRTIs were identified during the 2-year study period, of which 94 (9%) were caused by RSV A and 132 (13%) by RSV B. Associations between CB nAb levels and RSV infection will be presented.
Conclusion :
Neutralizing Ab to RSV A and B was present at birth in infants from 8 countries, and waned over time. GMTs were at a nadir at 6 to 12 months of age.
Funding: GlaxoSmithKline Biologicals SA
.png)
.png)